Next, we divided the tumor patients into high- and low-expression groups according to the optimal cut-offs in CYB561 and FOLH1 (4.67 in CYB561, 2.64 in FOLH1) for clinical prognostic analysis. The gene discussed is FOLH1; the disease is neoplasm.